Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108600 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab for Renal Graft Inflammation
A Phase 2 study of Late Complication From Kidney Transplant, sponsored by Flavio Vincenti.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT02108600 is a Phase 2 study of Late Complication From Kidney Transplant that has completed, run by Flavio Vincenti. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02108600, a Phase 2 study of Late Complication From Kidney Transplant, has completed, sponsored by Flavio Vincenti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.
Conditions Studied
Interventions
- DRUG Tocilizumab
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02108600
The ClinicalTrials.gov registry entry for NCT02108600 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Flavio Vincenti, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Late Complication From Kidney Transplant appearing as the primary indexed condition, and to 1 intervention - of which Tocilizumab is the first listed.
NCT02108600 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02108600 about?
NCT02108600 is a clinical study titled "Tocilizumab for Renal Graft Inflammation". Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.
What is the current status of trial NCT02108600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2014-06. Estimated completion is 2018-12-16.
What conditions does trial NCT02108600 study?
This clinical trial studies the following conditions: Late Complication From Kidney Transplant.
What interventions are being tested in trial NCT02108600?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02108600?
This trial is sponsored by Flavio Vincenti, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02108600 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.